ACORライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (12 4月 2024 @ 05:00):

Stats
本日の出来高	321 668
平均出来高	139 878
時価総額	821 028
EPS	$0 ( 2024-04-01 )
次の収益日	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0120 (1.96%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-22	Burns Thomas M.	Buy	2 400	Non-Employee Stock Option
2023-06-22	Burns Thomas M.	Buy	0
2023-06-22	Varian John	Buy	1 200	Non-Employee Stock Option
2023-06-22	Panem Sandra Phd	Buy	1 200	Non-Employee Stock Option
2023-06-22	Kelley John P	Buy	1 200	Non-Employee Stock Option

INSIDER POWER
99.33
Last 96 transactions
Buy: 1 532 806 \| Sell: 94 790

ボリューム相関

長: -0.43 (neutral)

短: -0.79 (moderate negative)

Signal:(18.947) Neutral

Acorda Therapeutics Inc 相関

10 最も正の相関
HCTI	0.95
TVTX	0.945
ALBO	0.939
MNST	0.934
CMPI	0.93
GNLN	0.929
APLT	0.929
MORF	0.924
SBET	0.922
UFO	0.922

10 最も負の相関
NTGR	-0.928
PI	-0.928
ATRS	-0.919
PPBT	-0.916
HONE	-0.912
CPSI	-0.912
BRAC	-0.908
KDNY	-0.907
MSAC	-0.903
LGTO	-0.901

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Acorda Therapeutics Inc 相関 - 通貨/商品

0.58
( weak )

-0.02
( neutral )

0.00
( neutral )

0.27
( neutral )

-0.29
( neutral )

-0.06
( neutral )

Acorda Therapeutics Inc 財務諸表

Annual	2023
収益:	$117.63M
総利益:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2023
収益:	$117.63M
総利益:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2022
収益:	$118.57M
総利益:	$88.23M (74.42 %)
EPS:	$-66.90

FY	2021
収益:	$129.07M
総利益:	$88.28M (68.40 %)
EPS:	$-12.86

Financial Reports:

No articles found.

Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

リアルタイムの更新： Acorda Therapeutics Inc [ACOR]

Upcoming Earnings Alert